+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Tau Pipeline Enabling Program V (T-PEP)

Alzheimer's Association

T-PEP supports translational projects aimed at advancing potential therapies for tauopathies, including Alzheimer's disease, progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). The program focuses on development candidate selection, lead optimization, in vivo proof-of-concept, and IND-enabling studies for tau or tau-related mechanisms. Projects centered on compound or target discovery are not responsive.

Program overview

The Tau Pipeline Enabling Program (T-PEP) seeks to accelerate the discovery of potential new therapies for tauopathies. This program intends to enrich the pipeline for therapy development by facilitating the translation of academia-derived ideas into practical application. In short, T-PEP bridges the gap between innovative but resource-constrained researchers and the larger pharmaceutical companies that are looking for drug candidates to be taken into human trials.

The overarching goal of T-PEP is to promote the advanced study of a wide range of novel targets, agents, and/or therapeutic strategies that will accelerate the development of disease-modifying interventions for tauopathies.

Key dates and deadlines

All deadlines are 5 p.m. ET. Late submissions will not be accepted.

Letter of Intent launch: April 13, 2026
Letter of Intent deadline: May 28, 2026
Full application deadline: Aug. 14, 2026
Application review: Sept./Oct. 2026
Award notifications: Nov. 30, 2026

Funding overview

Maximum award: $750,000
Project duration: Up to 2 years
Nonprofits may request up to 10% indirect costs. Indirect costs are not allowed for for-profit entities.
Funds must support candidate development activities and milestone-driven translational work.

Application process

A Letter of Intent is required and must be submitted through ProposalCentral. Only applicants invited after LOI review may submit a full application.
Full applications must be submitted online through ProposalCentral and include program-specific materials described in the RFA.

Application review process

LOIs and full applications are reviewed for program alignment, scientific rationale, methodological rigor, translational path, milestones, and potential impact on tauopathies.

Additional information

Applicants should review the full RFA for detailed eligibility, application requirements, budget guidance, milestone expectations, and required attachments.
All applicants and institutions are strongly encouraged to review the Conditions of Award before submitting an LOI.

AI Based Application Success Predictor

🧠 1. Strong Focus on Alzheimer’s Disease & Related Dementias (Non-Negotiable)

Projects must directly address:
- Alzheimer’s disease (AD) or:
- Alzheimer’s disease and related dementias (ADRD)
Includes:
- Diagnosis
- Prevention
- Treatment
- Care and quality of life

👉 Non-dementia neuroscience → low success probability

🔄 2. Strong Translational Pathway (Top Predictor)

The Association funds:
- Basic science → translational → clinical → care research
Increasing emphasis on:
- Translational research and clinical interventions

👉 Key question:
“How will this improve diagnosis, prevention, treatment, or patient care?”

🎯 3. Clear Clinical or Patient Impact (Critical)

Successful proposals usually:

Improve:
- Early diagnosis
- Therapeutic strategies
- Dementia care
- Prevention approaches

👉 Patient benefit is a major scoring factor

🚀 4. Innovation & High-Risk, High-Reward Science

The Alzheimer’s Association actively funds:
- Novel and breakthrough ideas
Especially through:
- Part the Cloud (PTC) initiatives for translational trials

👉 Incremental proposals are less competitive

🧬 5. High Priority Areas: Biomarkers, Early Detection & Therapeutics

Frequently funded areas:

Blood-based biomarkers
Neuroimaging
Precision medicine
Disease-modifying therapies
Early prediction models

👉 Early detection and therapeutic development are especially competitive

👩‍🔬 6. Early-Career Investigator Development (Major Priority)

The Association strongly supports:
- Postdocs
- Junior faculty
- New investigators entering dementia research

👉 Career development potential is heavily weighted

🤝 7. Strong Mentorship & Research Environment

Fellowship and early-career awards require:
- Structured mentorship
- Institutional support
Strong mentors improve competitiveness substantially

🌍 8. Broad Research Scope Including Care & Health Equity

Unlike some neurodegeneration funders, the Alzheimer’s Association funds:

Social-behavioral research
Care interventions
Public health and prevention
Health equity studies

👉 Community and caregiving research can be highly competitive if impactful

🧪 9. Feasible, Well-Designed Pilot Research

Many awards are:
- Pilot or career-development grants
Strong proposals include:
- Clear aims
- Realistic timelines
- Preliminary rationale

👉 Overly ambitious projects are commonly rejected

📈 10. Potential for Future NIH or Major Funding

Alzheimer’s Association grants are often:
- Seed funding mechanisms
Strong proposals:
- Generate pilot data for:
  - NIH R01s
  - Clinical trials
  - Large consortium grants

🌐 11. International & Collaborative Research Advantage

The program is:
- International in scope
Encourages:
- Cross-institutional and multidisciplinary collaboration

👉 Collaboration strengthens competitiveness, especially for translational projects

📊 Summary: Key Predictors (Ranked)

🔥 Highest impact factors:

Alzheimer’s/ADRD-specific focus
Translational relevance
Clear patient or clinical impact

⚖️ Major differentiators:

Innovation/high-risk ideas
Biomarker or therapeutic relevance
Early-career investigator development

📌 Supporting factors:

Mentorship quality
Feasibility
Future funding potential
Collaboration

💡 Insider Insight

Compared to NIH:

Alzheimer's Association is:
👉 more willing to fund:
- Early-stage ideas
- Pilot studies
- High-risk concepts
Strongly focused on:
- Career development
- Translational impact

👉 Winning formula:
Innovative AD-focused project + translational pathway + strong mentorship + feasible pilot design

✔️ What wins:

Biomarker and early detection studies
Translational therapeutic research
Innovative pilot projects with clinical potential
Care and health equity interventions with measurable impact

❌ What struggles:

Non-AD neuroscience
Pure basic science without translational relevance
Weak clinical significance
Overly broad or unrealistic proposals

Specialties

Neurosciences

Eligibility Requirements

Academic institutions, nonprofit organizations, and small for-profit companies may apply. Preference is given to companies with 50 or fewer employees.
The principal investigator must be considered a full-time employee of the applicant organization. Postdoctoral applicants are not eligible to serve as PI but may be included as key personnel.
Applicants must provide documentation confirming nonprofit or for-profit status.

Sponsor Details

Sponsor Institute/Organizations: Alzheimer's Association

Sponsor Type: Corporate/Non-Profit

Address: 225 N Michigan Ave. Floor 17 Chicago, IL 60601 800.272.3900

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity